Literature DB >> 15556566

Diosgenin dose-dependent apoptosis and differentiation induction in human erythroleukemia cell line and sedimentation field-flow fractionation monitoring.

David Yannick Léger1, Bertrand Liagre, Philippe Jean Paul Cardot, Jean-Louis Beneytout, Serge Battu.   

Abstract

To limit or stop cancer spreading, one of the most prevalent strategies is to induce cancer cell death. Differentiation therapy and apoptosis induction are two ways to achieve this goal. Sedimentation field-flow fractionation (SdFFF) has been described as an effective tool for cell separation, respecting integrity and viability. Because SdFFF takes advantage of intrinsic properties of eluted cells (size, density, shape), we studied the capacity of SdFFF to monitor specific biophysical modifications that occurred during cellular apoptosis or differentiation induction. Then, we used, as an in vitro cellular model of apoptosis and differentiation, diosgenin dose-dependent induction in the polyvalent human erythroleukemia cell line. Two other chemicals were used: phorbol myristate acetate (differentiation inducer) and staurosporine (apoptosis inducer). Our results demonstrated a correlation between SdFFF elution profile changes and induction of effective biological processes. Thus, after acquisition of a reference profile, SdFFF could be used alone to follow chemically induced biological events, suggesting many different applications such as testing series of molecules, evaluation of new cellular/biological models used in different life science fields, or sorting purified populations with the aim of better understanding mechanisms of induced cellular events.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15556566     DOI: 10.1016/j.ab.2004.09.008

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  7 in total

1.  Diosgenin-loaded niosome as an effective phytochemical nanocarrier: physicochemical characterization, loading efficiency, and cytotoxicity assay.

Authors:  Mohammad Reza Hajizadeh; Najmeh Parvaz; Mahmood Barani; Alireza Khoshdel; Mohammad Ali Fahmidehkar; Mehdi Mahmoodi; Masoud Torkzadeh-Mahani
Journal:  Daru       Date:  2019-05-27       Impact factor: 3.117

2.  Diosgenin Suppresses Cholangiocarcinoma Cells Via Inducing Cell Cycle Arrest And Mitochondria-Mediated Apoptosis.

Authors:  Xiao-Mei Mao; Pan Zhou; Si-Yang Li; Xiao-Yun Zhang; Jin-Xing Shen; Qing-Xi Chen; Jiang-Xing Zhuang; Dong-Yan Shen
Journal:  Onco Targets Ther       Date:  2019-11-04       Impact factor: 4.147

3.  Diosgenin, a steroidal saponin, inhibits migration and invasion of human prostate cancer PC-3 cells by reducing matrix metalloproteinases expression.

Authors:  Pin-Shern Chen; Yuan-Wei Shih; Hsiang-Ching Huang; Hsing-Wen Cheng
Journal:  PLoS One       Date:  2011-05-23       Impact factor: 3.240

Review 4.  Diosgenin: Recent Highlights on Pharmacology and Analytical Methodology.

Authors:  Mafalda Jesus; Ana P J Martins; Eugenia Gallardo; Samuel Silvestre
Journal:  J Anal Methods Chem       Date:  2016-12-28       Impact factor: 2.193

5.  Involvement of autophagy in diosgenin‑induced megakaryocyte differentiation in human erythroleukemia cells.

Authors:  Bertrand Liagre; David Yannick Leger; Dima Diab; Aline Pinon; Catherine Ouk; Rouba Hage-Sleiman; Mona Diab-Assaf
Journal:  Mol Med Rep       Date:  2021-08-30       Impact factor: 2.952

6.  Diosgenin From Dioscorea Nipponica Rhizoma Against Graves' Disease-On Network Pharmacology and Experimental Evaluation.

Authors:  Jingxin Xin; Wencong Cheng; Yongbing Yu; Juan Chen; Xinhuan Zhang; Shanshan Shao
Journal:  Front Pharmacol       Date:  2022-01-24       Impact factor: 5.810

Review 7.  Possible Anticancer Mechanisms of Some Costus speciosus Active Ingredients Concerning Drug Discovery.

Authors:  Ali H El-Far; Faried A Badria; Hazem M Shaheen
Journal:  Curr Drug Discov Technol       Date:  2016
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.